Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Sell
28
ATRC Quote, Financials, Valuation and Earnings
Last price:
$33.50
Seasonality move
:
16.01%
Day range:
$33.45 - $35.24
52-week range:
$18.94 - $43.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.39x
P/B ratio:
3.56x
Volume:
956.5K
Avg. volume:
604.9K
1-year change:
12.82%
Market cap:
$1.6B
Revenue:
$465.3M
EPS (TTM):
-$0.95
Analysts' Opinion
-
Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $54.22, AtriCure has an estimated upside of 61.66% from its current price of $33.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $45.00 representing -34.17% downside risk from its current price of $33.54.
Fair Value
-
According to the consensus of 5 analysts, AtriCure has 61.66% upside to fair value with a price target of $54.22 per share.
ATRC vs. S&P 500
-
Over the past 5 trading days, AtriCure has overperformed the S&P 500 by 0.18% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
AtriCure does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AtriCure has grown year-over-year revenues for 16 quarters straight. In the most recent quarter AtriCure reported revenues of $124.3M.
Earnings Growth
-
AtriCure has grown year-over-year earnings for 0 quarters straight. In the most recent quarter AtriCure reported earnings per share of -$0.33.
Enterprise value:
1.6B
EV / Invested capital:
3.01x
Price / LTM sales:
3.39x
EV / EBIT:
--
EV / Revenue:
3.40x
PEG ratio (5yr expected):
-0.80x
EV / Free cash flow:
-140.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$347.5M
Return On Assets:
-7.38%
Net Income Margin (TTM):
-9.61%
Return On Equity:
-9.67%
Return On Invested Capital:
-8.52%
Operating Margin:
-11.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $330.4M | $399.2M | $465.3M | $106.5M | $124.3M | |
| Gross Profit | $245.9M | $300.4M | $347.5M | $79.8M | $92.6M | |
| Operating Income | -$42.7M | -$26.7M | -$40M | -$8.7M | -$14.5M | |
| EBITDA | -$29.5M | -$8.1M | -$18.5M | -$3.4M | -$9M | |
| Diluted EPS | -$1.01 | -$0.66 | -$0.95 | -$0.21 | -$0.33 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $306.7M | $196.1M | $215.2M | $266.2M | $267.8M | |
| Total Assets | $714.5M | $615.3M | $585.4M | $613.9M | $609.3M | |
| Current Liabilities | $49.1M | $56.4M | $58.4M | $74.6M | $73.4M | |
| Total Liabilities | $302.1M | $131.6M | $128.7M | $147.8M | $148.4M | |
| Total Equity | $412.4M | $483.8M | $456.8M | $466.2M | $461M | |
| Total Debt | $61.9M | $59.7M | $62.3M | $63.1M | $64.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.1M | $4.5M | $12.2M | $4M | $5.8M | |
| Cash From Investing | $44M | $21.8M | $30.2M | -$2.8M | -$14.7M | |
| Cash From Financing | -$7.1M | -$32K | -$3.6M | $2.4M | $1.7M | |
| Free Cash Flow | -$39M | -$37.5M | -$11.3M | $1.2M | -$8.9M | |
ATRC
Sector
Market Cap
$1.6B
$39.2M
Price % of 52-Week High
77.8%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
0.44%
-0.81%
1-Year Price Total Return
12.82%
-38.63%
Beta (5-Year)
1.535
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$33.71
200-day SMA
Buy
Level
$30.12
Bollinger Bands (100)
Sell
Level
31.95 - 39.33
Chaikin Money Flow
Buy
Level
30.1M
20-day SMA
Sell
Level
$36.17
Relative Strength Index (RSI14)
Sell
Level
37.26
ADX Line
Sell
Level
28.9
Williams %R
Buy
Level
-80.2817
50-day SMA
Sell
Level
$37.80
MACD (12, 26)
Sell
Level
-1.33
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
49.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.0614)
Buy
CA Score
(Annual)
Level (0.743)
Buy
Beneish M-Score
(Annual)
Level (-2.8024)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.8004)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Stock Forecast FAQ
In the current month, ATRC has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ATRC average analyst price target in the past 3 months is $54.22.
-
Where Will AtriCure Stock Be In 1 Year?
According to analysts, the consensus estimate is that AtriCure share price will rise to $54.22 per share over the next 12 months.
-
What Do Analysts Say About AtriCure?
Analysts are divided on their view about AtriCure share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AtriCure is a Sell and believe this share price will drop from its current level to $45.00.
-
What Is AtriCure's Price Target?
The price target for AtriCure over the next 1-year time period is forecast to be $54.22 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ATRC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AtriCure is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ATRC?
You can purchase shares of AtriCure via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AtriCure shares.
-
What Is The AtriCure Share Price Today?
AtriCure was last trading at $33.50 per share. This represents the most recent stock quote for AtriCure. Yesterday, AtriCure closed at $33.54 per share.
-
How To Buy AtriCure Stock Online?
In order to purchase AtriCure stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CyberArk Stock a Buy, Sell or Hold?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…
Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 20
Regencell Bioscience Holdings [RGC] is down 0% over the past day.
Sell
36
VMI alert for Mar 20
Valmont Industries [VMI] is down 0% over the past day.
Buy
61
ALNY alert for Mar 20
Alnylam Pharmaceuticals [ALNY] is down 0% over the past day.
